IL1B and Bloom syndrome: Treatment of NLRP3-AID targets on inhibition of the inflammasome-derived cytokine IL-1β (9), which drives autoinflammatory processes and also acts on the effector cells of the adaptive immune system, while TNF-α inhibitors are widely accepted as efficacious therapy for refractory BS.